Clinical Progress in Chronic Pulmonary Heart Disease 1986.5.19

Clinical Progress in Chronic Pulmonary Heart Disease 1986.5.19

In 1961, the International Conference on Pulmonary Heart Disease defined this condition as right ventricular hypertrophy caused by chronic respiratory diseases. In 1975, the European Conference on Pulmonary Heart Disease proposed that pulmonary heart disease is right ventricular hypertrophy resulting from reduced pulmonary vascular bed capacity. This disease has a high incidence and poor prognosis. BoudⅠk followed up 829 cases of pulmonary heart disease for two years, finding that one-third died; after four years, two-thirds had died, with only two surviving for six years. The disease predominantly affects the elderly and middle-aged, though young people can also be affected, albeit rarely. Clinical symptoms, aside from common respiratory symptoms, prominently include edema and somnolence. Physical signs, beyond emphysema and pulmonary heart disease signs, notably include rapid heart rate and hepatomegaly. Laboratory tests reveal increased hemoglobin, total white blood cell count, and neutrophil count. Non-protein nitrogen increases in 39.5% of cases, and blood gas analysis shows respiratory acidosis in 58.6% of cases, with some also having metabolic acidosis or alkalosis. ECG changes include clockwise rotation, rightward electrical axis, right ventricular hypertrophy, ST segment alterations, and arrhythmias—all decreasing in frequency from 90% to 10%.